BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BioCentury  |  Regulation

Belatacept Trial Designs

Belatacept Trial Designs

Study Population Patients Primary endpoints Secondary endpoints
IM103027 Recipients of kidneys from deceased donors considered high risk, including organs from donors older than 60 or from...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >